## FOOD AND DRUG ADMINISTRATION (FDA)

Center for Biologics Evaluation and Research (CBER)
169<sup>th</sup> Meeting of the Vaccines and Related Biological Products
Advisory Committee
October 14-15, 2021
DRAFT AGENDA

October 14, 2021:Topic 1: The committee will meet in open session to discuss the EUA of the Moderna COVID-19 mRNA Vaccine for the administration of an booster dose, following completion of the primary series, in individuals 18 years of age and older.

Time	Presentation/Presenter
8:30 a.m.	Opening Remarks: Call to Order and Welcome (10 min)
	Arnold Monto, M.D. Acting Chair, VRBPAC
	Professor of Public Health and Epidemiology, University of Michigan
	Administrative Announcements, Roll Call, Introduction of Committee,
	Conflict of Interest Statement (20 min)
	Prabhakara Atreya, Ph.D. Acting Designated Federal Officer, VRBPAC Director, Division Scientific Advisors and Consultants, CBER, FDA
	Director, Division Scientific Advisors and Consultants, CBEIX, 1 DA
9:00 a.m.	FDA Introduction (30 min)
	•
	Introduction of the Topic (10 Min)
	Peter Marks, M.D. Ph.D.
	Center Director
	CBER, FDA
	Background (15 Min)
	Sudhakar Agnihothram, Ph.D.
	Division of Vaccines and Related Product Applications (DVRPA),
	OVRR, CBER, FDA
	, ,
	● Q/A – 5 Min
9:30 a.m.	Presentation of Data Relevant to the Need for Boosters (60 Min)
	Dres entation of Lindated Israeli Vassination Data (40 Min)
	Presentation of Updated Israeli Vaccination Data (40 Min)
	<ul> <li>Speaker 1: Sharon Alroy, M.D., M.P.H, M.B.A., Director of Public Health Services, Ministry of Health Israel</li> </ul>
	Speaker 2: Ron Milo, Ph.D., Professor, Weitzman Institute, Israel
	Speaker 2. Norrivillo, Fri. D., Froressor, Wellzmarrinstitute, Israel
	• Q/A - 20 min
10:30 am	BREAK (15min)

## FOOD AND DRUG ADMINISTRATION (FDA)

## Center for Biologics Evaluation and Research (CBER) 169<sup>th</sup> Meeting of the Vaccines and Related Biological Products Advisory Committee October 14-15, 2021 DRAFT AGENDA

10:45 am	Sponsor Presentation (45 Min)
	Safety and Immunogenicity of a 50 µg Booster Dose of mRNA-1273 (Moderna COVID-19 Vaccine)
	Jacqueline Miller, MD     ID Therapeutic Area Head,
	Moderna Therapeutics
11:30 am	FDA Presentation (45 min)
	Tina Mongeau, M.D., M.P.H.     Medical Officer
	Clinical Review Branch 1, DVRPA, OVRR, CBER
	<ul> <li>Hui-Lee Wong, Ph.D., Associate Director for Innovation Office of Biostatistics and Epidemiology, CBER, FDA</li> </ul>
	<ul> <li>Richard Forshee, Ph.D., Acting Deputy Director         Office of Biostatistics and Epidemiology,         CBER, FDA</li> </ul>
	• Q/A – 5 min
12:15 pm	Lunch (30 min)
12:45 pm	Open Public Hearing (60 min)
1:45 pm	Break (15 Min)
2:00 pm	Additional Q & A regarding Sponsor and FDA presentations (45 min)
2:45 pm	Committee Discussion and Voting (120 min)
4:45 pm	Meeting Adjourned